NCT03922555

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2019-07-12Est. Completion: 2027-01-01

Enrollment target: 18 participants

Locations

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Brigham and Women's Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Contact

Isabel Arrillaga-Romany, MDiarrillaga@mgh.harvard.edu 617-724-4000

Other microbiome trials you might be interested in

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaPhase 1Recruiting

Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed CancerRecurrent TumorGlioblastoma MultiformeRecurring GlioblastomaBrain and Central Nervous System TumorsGliomaGlioblastomasGrade IV AstrocytomaGBMRecurrent Glioma (Glioblastoma Multiforme)High Grade GliomaGlioma, MalignantBrain Cancer

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. B…

Bethesda, United StatesEst. completion Dec 31, 2030

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.